Tvaster Genkalp Secures $1.25 Million for Liver Cancer Detection Innovation

Healthtech startup Tvaster Genkalp has successfully completed a pre-Series A funding round, raising $1.25 million. This round, primarily led by Ideaspring Capital, saw participation from existing investors, including Invigo Softwares and renowned liver transplant expert Prof. Mohamed Rela.

The funding will be allocated to enhance the development and promotion of Episcreen Liver, an innovative blood test capable of detecting liver cancer at an impressive 90% accuracy rate. This breakthrough provides a superior alternative to the traditional Alpha-Fetoprotein (AFP) test, which only shows a 50% sensitivity rate.

About Tvaster Genkalp

Established in 2021 by Dr. Srikar Raman and K. Sreedurgalakshmi, Tvaster is dedicated to creating highly accurate, non-invasive cancer testing solutions. The company’s mission is to significantly enhance early detection rates and ultimately save lives, particularly in relation to liver cancer, which claims the lives of over 900,000 individuals worldwide each year.

Expansion Plans and Partnerships

Tvaster has conducted tests on Episcreen Liver involving over 600 patients and is set to collaborate with leading diagnostic laboratories to ensure broader accessibility. The company is also developing tests targeted at bile duct cancer and addressing treatment resistance in childhood liver cancer.

Awards and Recognition

Recently, Tvaster received the prestigious ILTS Young Researcher Award and secured a BIRAC BIG Grant in recognition of its innovative contributions to cancer diagnostics.